Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2018

01-03-2018 | Review Article

Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults

Author: Martin Holtkamp

Published in: Drugs | Issue 3/2018

Login to get access

Abstract

Patients with prolonged seizures that do not respond to intravenous benzodiazepines and a second-line anticonvulsant suffer from refractory status epilepticus and those with seizures that do not respond to continuous intravenous anesthetic anticonvulsants suffer from super-refractory status epilepticus. Both conditions are associated with significant morbidity and mortality. A strict pharmacological treatment regimen is urgently required, but the level of evidence for the available drugs is very low. Refractory complex focal status epilepticus generally does not require anesthetics, but all intravenous non-anesthetizing anticonvulsants may be used. Most descriptive data are available for levetiracetam, phenytoin and valproate. Refractory generalized convulsive status epilepticus is a life-threatening emergency, and long-term clinical consequences are eminent. Administration of intravenous anesthetics is mandatory, and drugs acting at the inhibitory gamma-aminobutyric acid (GABA)A receptor such as midazolam, propofol and thiopental/pentobarbital are recommended without preference for one of those. One in five patients with anesthetic treatment does not respond and has super-refractory status epilepticus. With sustained seizure activity, excitatory N-methyl-d-aspartate (NMDA) receptors are increasingly expressed post-synaptically. Ketamine is an antagonist at this receptor and may prove efficient in some patients at later stages. Neurosteroids such as allopregnanolone increase sensitivity at GABAA receptors; a Phase 1/2 trial demonstrated safety and tolerability, but randomized controlled data failed to demonstrate efficacy. Adjunct ketogenic diet may contribute to termination of difficult-to-treat status epilepticus. Randomized controlled trials are needed to increase evidence for treatment of refractory and super-refractory status epilepticus, but there are multiple obstacles for realization. Hitherto, prospective multicenter registries for pharmacological treatment may help to improve our knowledge.
Literature
1.
Neligan A, Shorvon SD. Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol. 2010;67:931–40.PubMedCrossRef
2.
Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792–8.PubMedCrossRef
3.
Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698–702.PubMedCrossRef
4.
Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534–9.PubMedPubMedCentralCrossRef
5.
Holtkamp M, Othman J, Buchheim K, Masuhr F, Schielke E, Meierkord H. A “malignant” variant of status epilepticus. Arch Neurol. 2005;62:1428–31.PubMedCrossRef
6.
Pugin D, Foreman B, De Marchis GM, Fernandez A, Schmidt JM, Czeisler BM, Mayer SA, Agarwal S, Lesch C, Lantigua H, Claassen J. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care. 2014;18:R103.PubMedPubMedCentralCrossRef
7.
Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia. 2017;58:1533–41.PubMedCrossRef
8.
Kantanen AM, Reinikainen M, Parviainen I, Ruokonen E, Ala-Peijari M, Backlund T, Koskenkari J, Laitio R, Kalviainen R. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav. 2015;49:131–4.PubMedCrossRef
9.
Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28.PubMedCrossRef
10.
Penberthy LT, Towne A, Garnett LK, Perlin JB, DeLorenzo RJ. Estimating the economic burden of status epilepticus to the health care system. Seizure. 2005;14:46–51.PubMedCrossRef
11.
Beg JM, Anderson TD, Francis K, Meckley LM, Fitzhenry D, Foster T, Sukhtankar S, Kanes SJ, Moura LM. Burden of illness for super-refractory status epilepticus patients. J Med Econ. 2017;20:45–53.PubMedCrossRef
12.
13.
Trinka E, Brigo F, Shorvon S. Recent advances in status epilepticus. Curr Opin Neurol. 2016;29:189–98.PubMedCrossRef
14.
15.
16.
17.
Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16:48–61.PubMedPubMedCentralCrossRef
18.
Verrotti A, Ambrosi M, Pavone P, Striano P. Pediatric status epilepticus: improved management with new drug therapies? Expert Opin Pharmacother. 2017;18:789–98.PubMedCrossRef
19.
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515–23.PubMedCrossRef
20.
Shorvon S. Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia. 2011;52(Suppl 8):53–6.PubMedCrossRef
21.
Walton NY. Systemic effects of generalized convulsive status epilepticus. Epilepsia. 1993;34(Suppl 1):S54–8.PubMedCrossRef
22.
DeLorenzo RJ, Garnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton L, Choudhry MA, Barnes T, Ko D. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40:164–9.PubMedCrossRef
23.
Treiman DM, Walton NY, Kendrick C. A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus. Epilepsy Res. 1990;5:49–60.PubMedCrossRef
24.
Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol. 2007;6:329–39.PubMedCrossRef
25.
Bauer G, Gotwald T, Dobesberger J, Embacher N, Felber S, Bauer R, Seppi K, Walser G, Trinka E, Poewe W. Transient and permanent magnetic resonance imaging abnormalities after complex partial status epilepticus. Epilepsy Behav. 2006;8:666–71.PubMedCrossRef
26.
DeGiorgio CM, Gott PS, Rabinowicz AL, Heck CN, Smith TD, Correale JD. Neuron-specific enolase, a marker of acute neuronal injury, is increased in complex partial status epilepticus. Epilepsia. 1996;37:606–9.PubMedCrossRef
27.
DeGiorgio CM, Heck CN, Rabinowicz AL, Gott PS, Smith T, Correale J. Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology. 1999;52:746–9.PubMedCrossRef
28.
Kucken AM, Teissere JA, Seffinga-Clark J, Wagner DA, Czajkowski C. Structural requirements for imidazobenzodiazepine binding to GABA(A) receptors. Mol Pharmacol. 2003;63:289–96.PubMedCrossRef
29.
Macdonald RL. Mechanisms of anticonvulsant drug action. In: Pedley TA, Meldrum BS, editors. Recent advances in epilepsy I. Edinburgh: Churchill Livingstone; 1983. p. 1–23.
30.
Barker J, Owen DG. Electrophysiological pharmacology of GABA and diazepam in cultured CNS neurons. In: Olsen RW, Venter JC, editors. Benzodiazepine/GABA receptors and chloride channels: structural and functional properties. New York: Alan R. Liss; 1986. p. 135–65.
31.
Porter RJ, Dhir A, Macdonald RL, Rogawski MA. Mechanisms of action of antiseizure drugs. Handb Clin Neurol. 2012;108:663–81.PubMedCrossRef
32.
Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814:179–85.PubMedCrossRef
33.
Walton NY, Treiman DM. Lorazepam treatment of experimental status epilepticus in the rat: relevance to clinical practice. Neurology. 1990;40:990–4.PubMedCrossRef
34.
Celesia GG, Booker HE, Sato S. Brain and serum concentrations of diazepam in experimental epilepsy. Epilepsia. 1974;15:417–25.PubMedCrossRef
35.
36.
Milovanovic JR, Jankovic SM, Pejcic A, Milosavljevic M, Opancina V, Radonjic V, Protrka Z, Kostic M. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother. 2017;18:1381–9.PubMedCrossRef
37.
Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De RM, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57:538–48.PubMedCrossRef
38.
Niquet J, Suchomelova L, Thompson K, Klitgaard H, Matagne A, Wasterlain C. Acute and long-term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus. Epilepsia. 2017;58:1199–207.PubMedCrossRef
39.
Klein P, Biton V, Dilley D, Barnes M, Schiemann J, Lu S. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 2016;57:1130–8.PubMedCrossRef
40.
Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med. 2003;348:2110–24.PubMedCrossRef
41.
Grasshoff C, Antkowiak B. Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. Br J Anaesth. 2006;97:687–94.PubMedCrossRef
42.
Murao K, Shingu K, Tsushima K, Takahira K, Ikeda S, Matsumoto H, Nakao S, Asai T. The anticonvulsant effects of volatile anesthetics on penicillin-induced status epilepticus in cats. Anesth Analg. 2000;90:142–7.PubMedCrossRef
43.
Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25:7724–33.PubMedCrossRef
44.
Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5:246–56.PubMedCrossRef
45.
Walker MC, Fisher A. Mechanisms of antiepileptic drug action. In: Shorvon S, Perucca E, Fish D, Dodson E, editors. The treatment of epilepsy. Oxford: Blackwell Publishing; 2004. p. 96–119.CrossRef
46.
Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev. 1999;51:7–61.PubMed
47.
48.
Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia. 2008;49:248–55.PubMedCrossRef
49.
Niquet J, Baldwin R, Norman K, Suchomelova L, Lumley L, Wasterlain CG. Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits. Epilepsia. 2016;57:1406–15.PubMedPubMedCentralCrossRef
50.
Rogawski MA, Tofighy A, White HS, Matagne A, Wolff C. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189–205.PubMedCrossRef
51.
Holtkamp D, Opitz T, Niespodziany I, Wolff C, Beck H. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na+ channel inactivation. Epilepsia. 2017;58:27–41.PubMedCrossRef
52.
Wasterlain CG, Stohr T, Matagne A. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res. 2011;94:10–7.PubMedPubMedCentralCrossRef
53.
Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures. Epilepsia. 2013;54:58–65.PubMedCrossRef
54.
Li W, Stefan H, Matzen J, Rampp S, Heinze HJ, Schmitt FC. Rapid loading of intravenous lacosamide: efficacy and practicability during presurgical video-EEG monitoring. Epilepsia. 2013;54:75–80.PubMedCrossRef
55.
56.
Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivates. Science. 1937;85:525–6.PubMedCrossRef
57.
Everett GM, Richards RK. Comparative anticonvulsant action of 3,5,5,-trimethyloxazolidine-2-4-dione (tridone), dilantin and phenobarbital. J Pharmacol Exp Ther. 1944;1:402–7.
58.
Brown WC, Schiffman DO, Swinyard EA, Goodman LS. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther. 1953;1953(107):273–83.
59.
Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217–27.PubMedCrossRef
60.
Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG. Anticonvulsant effects of levetiracetam and levetiracetam–diazepam combinations in experimental status epilepticus. Epilepsy Res. 2004;58:167–74.PubMedCrossRef
61.
Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia. 2009;50:415–21.PubMedCrossRef
62.
Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci. 2004;5:553–64.PubMedCrossRef
63.
Cossart R, Bernard C, Ben-Ari Y. Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies. Trends Neurosci. 2005;28:108–15.PubMedCrossRef
64.
Rogers CJ, Twyman RE, Macdonald RL. Benzodiazepine and beta-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J Physiol. 1994;475:69–82.PubMedPubMedCentralCrossRef
65.
66.
Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol. 1989;25:213–20.PubMedCrossRef
67.
Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958. Epilepsia. 2009;50(Suppl 3):69–92.PubMedCrossRef
68.
Kumbier E, Haack K. From a hypnotic to an antiepileptic drug—the discovery of the antiepileptic effect of phenobarbital by Alfred Hauptmann. Akt Neurol. 2004;31:302–6.CrossRef
69.
Hauptmann A. Luminal bei epilepsie. Mnch Med Wochenschr. 1912;59:1907–9.
70.
Hauptmann A. Erfahrungen aus der Behandlung der Epilepsie mit Luminal. Mnch Med Wochenschr. 1919;46:1319–21.
71.
Walton NY, Treiman DM. Phenobarbital treatment of status epilepticus in a rodent model. Epilepsy Res. 1989;4:216–21.PubMedCrossRef
72.
Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36(Suppl 2):S2–12.PubMedCrossRef
73.
Kuo CC. A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol. 1998;54:712–21.PubMed
74.
Holtkamp M, Meierkord H. Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell Mol Life Sci. 2007;64:2023–41.PubMedCrossRef
75.
Hara M, Kai Y, Ikemoto Y. Propofol activates GABAA receptor-chloride ionophore complex in dissociated hippocampal pyramidal neurons of the rat. Anesthesiology. 1993;79:781–8.PubMedCrossRef
76.
Adodra S, Hales TG. Potentiation, activation and blockade of GABAA receptors of clonal murine hypothalamic GT1-7 neurones by propofol. Br J Pharmacol. 1995;115:953–60.PubMedPubMedCentralCrossRef
77.
Orser BA, Wang LY, Pennefather PS, MacDonald JF. Propofol modulates activation and desensitization of GABAA receptors in cultured murine hippocampal neurons. J Neurosci. 1994;14:7747–60.PubMed
78.
Hara M, Kai Y, Ikemoto Y. Enhancement by propofol of the gamma-aminobutyric acidA response in dissociated hippocampal pyramidal neurons of the rat. Anesthesiology. 1994;81:988–94.PubMedCrossRef
79.
Holtkamp M, Tong X, Walker MC. Propofol in subanesthetic doses terminates status epilepticus in a rodent model. Ann Neurol. 2001;49:260–3.PubMedCrossRef
80.
Study RE, Barker JL. Diazepam and (–)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of gamma-aminobutyric acid responses in cultured central neurons. Proc Natl Acad Sci USA. 1981;78:7180–4.PubMedCrossRef
81.
Holtkamp M. The anaesthetic and intensive care of status epilepticus. Curr Opin Neurol. 2007;20:188–93.PubMedCrossRef
82.
Godin Y, Heiner L, Mark J, Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem. 1969;16:869–73.PubMedCrossRef
83.
Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int. 2000;37:103–10.PubMedCrossRef
84.
Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res. 1989;501:198–203.PubMedCrossRef
85.
Walton NY, Treiman DM. Valproic acid treatment of experimental status epilepticus. Epilepsy Res. 1992;12:199–205.PubMedCrossRef
86.
Hussein Z, Mukherjee D, Lamm J, Cavanaugh JH, Granneman GR. Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation. J Clin Pharmacol. 1994;34:754–9.PubMedCrossRef
87.
Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, Gottwald MD, O’Neil N, Neuhaus JM, Segal MR, Lowenstein DH. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631–7.PubMedCrossRef
88.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600.PubMedPubMedCentralCrossRef
89.
Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, An K, Bolgert F, Treluyer JM, Baulac M, Carli P. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15:47–55.PubMedCrossRef
90.
Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249:1452–4.PubMedCrossRef
91.
Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16:527–32.PubMedCrossRef
92.
Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, Ren Y, Fan CQ. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18:1391–6.PubMedCrossRef
93.
Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64:110–5.PubMedCrossRef
94.
Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure. 2014;23:167–74.PubMedCrossRef
95.
Strzelczyk A, Zollner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, Rosenow F, Bauer S. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58:933–50.PubMedCrossRef
96.
Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, Gaida B, von Podewils F, Rosenow F. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70:177–81.PubMedCrossRef
97.
Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, Fountain N, Jones E, Lowenstein D, Shinnar S, Silbergleit R, Treiman D, Trinka E, Kapur J. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89–92.PubMedPubMedCentralCrossRef
98.
Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, Treiman DM, Vespa PM. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3–23.PubMedCrossRef
99.
Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, Holtkamp M. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348–55.PubMedCrossRef
100.
Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, Katsarou N, Hamer HM. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42:714–8.PubMedCrossRef
101.
Ropper AH. Neurological und neurosurgical intensive care. 4th ed. Boston: Lippincott, Williams & Wilkins; 2003.
102.
Lovett EJ III, Alderman J, Munster E, Lundy J. Suppressive effects of thiopental and halothane on specific arms of the immune response. J Surg Oncol. 1980;15:327–34.PubMedCrossRef
103.
Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82:656–64.PubMedPubMedCentralCrossRef
104.
Holtkamp M. Should barbiturates be used in refractory status epilepticus? J Clin Neurophysiol. 2016;33:22–4.PubMedCrossRef
105.
Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21:233–6.PubMedCrossRef
106.
Ramsay RE, Wilder BJ, Uthman BM, Garnett WR, Pellock JM, Barkley GL, Leppik IE, Knapp LE. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res. 1997;28:181–7.PubMedCrossRef
107.
Wilder BJ, Campbell K, Ramsay RE, Garnett WR, Pellock JM, Henkin SA, Kugler AR. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol. 1996;53:764–8.PubMedCrossRef
108.
Moreno Morales EY, Fernandez PM, Bondy Pena EC, Dominguez Lorenzo JM, Pardellas SE, Fernandez A. Observational study of intravenous lacosamide in patients with convulsive versus non-convulsive status epilepticus. Clin Drug Investig. 2015;35:463–9.PubMedCrossRef
109.
Garces M, Villanueva V, Mauri JA, Suller A, Garcia C, Lopez Gonzalez FJ, Rodriguez Osorio X, Fernandez Pajarín G, Piera A, Guillamon E, Santafe C, Castillo A, Giner P, Torres N, Escalza I, Del Villar A, Garcia de Casasola MC, Bonet M, Noe E, Olmedilla N. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav. 2014;36:144–52.PubMedCrossRef
110.
Claassen J, Taccone FS, Horn P, Holtkamp M, Stocchetti N, Oddo M. Recommendations on the use of EEG monitoring in critically ill patients: consensus statement from the neurointensive care section of the ESICM. Intensive Care Med. 2013;39:1337–51.PubMedCrossRef
111.
Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146–53.PubMedCrossRef
112.
Rossetti AO, Milligan TA, Vulliemoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011;14:4–10.PubMedCrossRef
113.
Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 2001;57:1036–42.PubMedCrossRef
114.
Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, Hirsch LJ, Mayer SA, Claassen J. High-dose midazolam infusion for refractory status epilepticus. Neurology. 2014;82:359–65.PubMedPubMedCentralCrossRef
115.
Bellante F, Legros B, Depondt C, Creteur J, Taccone FS, Gaspard N. Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety. J Neurol. 2016;263:799–806.PubMedCrossRef
116.
Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci. 2002;23:177–82.PubMedCrossRef
117.
Parviainen I, Uusaro A, Kalviainen R, Mervaala E, Ruokonen E. Propofol in the treatment of refractory status epilepticus. Intensive Care Med. 2006;32:1075–9.PubMedCrossRef
118.
Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357:117–8.PubMedCrossRef
119.
Krajcova A, Waldauf P, Andel M, Duska F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care. 2015;19:398.PubMedPubMedCentralCrossRef
120.
Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29:1417–25.PubMedCrossRef
121.
Mirrakhimov AE, Voore P, Halytskyy O, Khan M, Ali AM. Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract. 2015;2015:260385.PubMedPubMedCentral
122.
Parviainen I, Uusaro A, Kalviainen R, Kaukanen E, Mervaala E, Ruokonen E. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59:1249–51.PubMedCrossRef
123.
Prabhakar H, Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus. Cochrane Database Syst Rev. 2017;2:CD009202.PubMed
124.
Ferlisi M, Hocker S, Grade M, Trinka E, Shorvon S. Preliminary results of the global audit of treatment of refractory status epilepticus. Epilepsy Behav. 2015;49:318–24.PubMedCrossRef
125.
Byun JI, Chu K, Sunwoo JS, Moon J, Kim TJ, Lim JA, Jun JS, Lee HS, Lee WJ, Lee DY, Jeon D, Lee ST, Jung KH, Jung KY, Lee SK. Mega-dose phenobarbital therapy for super-refractory status epilepticus. Epileptic Disord. 2015;17:444–52.PubMed
126.
Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, Al-Otaibi A, Kilbride R, Fernandez IS, Mendoza L, Samuel S, Zakaria A, Kalamangalam GP, Legros B, Szaflarski JP, Loddenkemper T, Hahn CD, Goodkin HP, Claassen J, Hirsch LJ. Laroche Sm. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54:1498–503.PubMedPubMedCentralCrossRef
127.
Höfler J, Rohracher A, Kalss G, Zimmermann G, Dobesberger J, Pilz G, Leitinger M, Kuchukhidze G, Butz K, Taylor A, Novak H, Trinka E. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs. 2016;30:869–76.PubMedPubMedCentralCrossRef
128.
Sabharwal V, Ramsay E, Martinez R, Shumate R, Khan F, Dave H, Iwuchukwu I, McGrade H. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav. 2015;52:264–6.PubMedCrossRef
129.
Hijazi Y, Bodonian C, Bolon M, Salord F, Boulieu R. Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury. Br J Anaesth. 2003;90:155–60.PubMedCrossRef
130.
Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol. 2004;61:1254–9.PubMedCrossRef
131.
Kofke WA, Young RS, Davis P, Woelfel SK, Gray L, Johnson D, Gelb A, Meeke R, Warner DS, Pearson KS. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology. 1989;71:653–9.PubMedCrossRef
132.
Zeiler FA, Zeiler KJ, Teitelbaum J, Gillman LM, West M. Modern inhalational anesthetics for refractory status epilepticus. Can J Neurol Sci. 2015;42:106–15.PubMedCrossRef
133.
Hanada T, Ido K, Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect. 2014;2:e00063.PubMedPubMedCentralCrossRef
134.
Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I, Dobesberger J, Novak H, Pilz G, Zerbs A, Trinka E. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav. 2015;49:354–8.PubMedCrossRef
135.
Redecker J, Wittstock M, Benecke R, Rosche J. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav. 2015;45:176–9.PubMedCrossRef
136.
Brigo F, Bragazzi NL, Igwe SC, Nardone R, Trinka E. Topiramate in the treatment of generalized convulsive status epilepticus in adults: a systematic review with individual patient data analysis. Drugs. 2017;77:67–74.PubMedCrossRef
137.
Kellinghaus C, Berning S, Stogbauer F. Use of oxcarbazepine for treatment of refractory status epilepticus. Seizure. 2014;23:151–4.PubMedCrossRef
138.
Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010;51:2207–10.PubMedCrossRef
139.
Walton NY, Jaing Q, Hyun B, Treiman DM. Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. Epilepsy Res. 1996;24:19–28.PubMedCrossRef
140.
Pruss H, Dalmau J, Harms L, Holtje M, Ahnert-Hilger G, Borowski K, Stoecker W, Wandinger KP. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010;75:1735–9.PubMedCrossRef
141.
Holzer FJ, Rossetti AO, Heritier-Barras AC, Zumsteg D, Roebling R, Huber R, Lerche H, Kiphuth IC, Bardutzky J, Bien CG, Troger M, Schoch G, Pruss H, Seeck M. Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol. 2012;68:310–7.PubMedCrossRef
142.
Gaspard N, Foreman BP, Alvarez V, Cabrera KC, Probasco JC, Jongeling AC, Meyers E, Espinera A, Haas KF, Schmitt SE, Gerard EE, Gofton T, Kaplan PW, Lee JW, Legros B, Szaflarski JP, Westover BM, Laroche SM, Hirsch LJ. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85:1604–13.PubMedPubMedCentralCrossRef
143.
Newman MP, Blum S, Wong RC, Scott JG, Prain K, Wilson RJ, Gillis D. Autoimmune encephalitis. Intern Med J. 2016;46:148–57.PubMedCrossRef
144.
Tollner K, Brandt C, Erker T, Loscher W. Bumetanide is not capable of terminating status epilepticus but enhances phenobarbital efficacy in different rat models. Eur J Pharmacol. 2015;746:78–88.PubMedCrossRef
145.
Pressler RM, Boylan GB, Marlow N, Blennow M, Chiron C, Cross JH, de Vries LS, Hallberg B, Hellstrom-Westas L, Jullien V, Livingstone V, Mangum B, Murphy B, Murray D, Pons G, Rennie J, Swarte R, Toet MC, Vanhatalo S, Zohar S. Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. Lancet Neurol. 2015;14:469–77.PubMedCrossRef
146.
147.
148.
Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, Hoffmann E, Colquhoun H, Doherty JJ, Kanes SJ. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82:342–52.PubMedPubMedCentralCrossRef
149.
150.
151.
Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347:1362–7.PubMedCrossRef
152.
153.
Gama IR, Trindade-Filho EM, Oliveira SL, Bueno NB, Melo IT, Cabral-Junior CR, Barros EM, Galvao JA, Pereira WS, Ferreira RC, Domingos BR, da Rocha AT. Effects of ketogenic diets on the occurrence of pilocarpine-induced status epilepticus of rats. Metab Brain Dis. 2015;30:93–8.PubMedCrossRef
154.
Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, Kaplan PW, Geocadin RG, Hartman AL, Venkatesan A, Cervenka MC. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82:665–70.PubMedPubMedCentralCrossRef
155.
Cervenka MC, Hocker S, Koenig M, Bar B, Henry-Barron B, Kossoff EH, Hartman AL, Probasco JC, Benavides DR, Venkatesan A, Hagen EC, Dittrich D, Stern T, Radzik B, Depew M, Caserta FM, Nyquist P, Kaplan PW, Geocadin RG. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology. 2017;88:938–43.PubMedCrossRef
156.
Volgushev M, Kudryashov I, Chistiakova M, Mukovski M, Niesmann J, Eysel UT. Probability of transmitter release at neocortical synapses at different temperatures. J Neurophysiol. 2004;92:212–20.PubMedCrossRef
157.
Yang XF, Ouyang Y, Kennedy BR, Rothman SM. Cooling blocks rat hippocampal neurotransmission by a presynaptic mechanism: observations using 2-photon microscopy. J Physiol. 2005;567:215–24.PubMedPubMedCentralCrossRef
158.
Schiff SJ, Somjen GG. The effects of temperature on synaptic transmission in hippocampal tissue slices. Brain Res. 1985;345:279–84.PubMedCrossRef
159.
Aihara H, Okada Y, Tamaki N. The effects of cooling and rewarming on the neuronal activity of pyramidal neurons in guinea pig hippocampal slices. Brain Res. 2001;893:36–45.PubMedCrossRef
160.
Liu Z, Gatt A, Mikati M, Holmes GL. Effect of temperature on kainic acid-induced seizures. Brain Res. 1993;631:51–8.PubMedCrossRef
161.
Schmitt FC, Buchheim K, Meierkord H, Holtkamp M. Anticonvulsant properties of hypothermia in experimental status epilepticus. Neurobiol Dis. 2006;23:689–96.PubMedCrossRef
162.
Kowski AB, Kanaan H, Schmitt FC, Holtkamp M. Deep hypothermia terminates status epilepticus–an experimental study. Brain Res. 2012;1446:119–26.PubMedCrossRef
163.
Zeiler FA, Zeiler KJ, Teitelbaum J, Gillman LM, West M. therapeutic hypothermia for refractory status epilepticus. Can J Neurol Sci. 2015;42:221–9.PubMedCrossRef
164.
Legriel S, Lemiale V, Schenck M, Chelly J, Laurent V, Daviaud F, Srairi M, Hamdi A, Geri G, Rossignol T, Hilly-Ginoux J, Boisrame-Helms J, Louart B, Malissin I, Mongardon N, Planquette B, Thirion M, Merceron S, Canet E, Pico F, Tran-Dinh YR, Bedos JP, Azoulay E, Resche-Rigon M, Cariou A. Hypothermia for neuroprotection in convulsive status epilepticus. N Engl J Med. 2016;375:2457–67.PubMedCrossRef
165.
Basha MM, Suchdev K, Dhakar M, Kupsky WJ, Mittal S, Shah AK. Acute resective surgery for the treatment of refractory status epilepticus. Neurocrit Care. 2017;27:370–80.PubMedCrossRef
Metadata
Title
Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults
Author
Martin Holtkamp
Publication date
01-03-2018
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0859-1

Other articles of this Issue 3/2018

Drugs 3/2018 Go to the issue

Review Article

Prevention and Treatment of Chronic Postsurgical Pain: A Narrative Review

Review Article

Efficacy and Safety of Tiotropium in Children and Adolescents

Adis Drug Evaluation

Landiolol: A Review in Tachyarrhythmias

AdisInsight Report

Netarsudil Ophthalmic Solution 0.02%: First Global Approval

Correction

Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Current Opinion

Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol